Delta-8 THC: The Legal-Loophole Cannabinoid That's Booming with Minimal Research | Research

The takeaway

Delta-8 THC exploded in popularity after the 2018 Farm Bill accidentally legalized it, but research is virtually nonexistent on its safety, potency, or health effects in humans.

Read this if you've used or considered delta-8 THC products — especially if you chose them thinking they were a safer or legal alternative to regular cannabis.

What the researchers found

Delta-8 THC exists in a remarkable regulatory gray zone. The 2018 U.S. Farm Bill legalized hemp (cannabis with less than 0.3% delta-9 THC) and its derivatives — which inadvertently legalized delta-8 THC, a psychoactive isomer of the more familiar delta-9 THC. The result has been an explosion of unregulated products in gas stations, convenience stores, and online retailers, with almost no scientific understanding of what consumers are actually ingesting.

This scoping review synthesized 103 documents spanning peer-reviewed studies, news reports, and anecdotal evidence. The findings are concerning on multiple levels. Most existing research used animal or cell models, not humans. The limited human data suggests delta-8 THC is psychoactive but possibly less potent than delta-9 THC, and people commonly use it as a substitute for delta-9 THC, particularly in states where recreational cannabis remains illegal.

The manufacturing side raises additional red flags. Delta-8 THC is typically synthesized from CBD extracted from hemp — a chemical conversion process that can produce unknown byproducts. Laboratory testing of commercial delta-8 products has found inconsistent potency labeling and the presence of unidentified compounds. Combined with youth-oriented marketing, low prices, and near-universal availability, delta-8 represents a large-scale natural experiment with minimal safety data.

The regulatory patchwork is equally chaotic: as of the review, some states had banned delta-8 while others allowed it, and federal guidance remained unclear.

Why it matters

Delta-8 THC products are already being used by millions of Americans, including adolescents, with virtually no human safety data. This review maps the enormous gap between how widely delta-8 is used and how little we actually know about it. For consumers, the takeaway is sobering: you're essentially a participant in an uncontrolled experiment.

The numbers in context

103 documents reviewed. Delta-8 was implicitly legalized by the 2018 Farm Bill. Most research used animal or cell models. Commercial products showed inconsistent potency labeling. Youth-oriented marketing was documented. Multiple states have enacted bans while others remain unregulated.

How the study worked

Scoping review using PubMed, Scopus, Google Scholar, and Google to identify 103 documents covering delta-8 THC. Documents were categorized into four emergent themes: legality, use (popularity, motives, psychoactivity, benefits/consequences), synthesis (byproducts, lab testing), and retail (availability, price, packaging, youth marketing). A second author independently coded 20% for verification.

Who was studied

103 documents reviewed, including peer-reviewed and anecdotal reports.

What this study cannot tell us

Scoping review methodology captures breadth but not depth — many sources were non-peer-reviewed (news reports, anecdotal evidence). The delta-8 landscape changes rapidly; legal status and product availability may already differ from what's described. Limited human pharmacological data means the review relies heavily on animal studies and self-reported user experiences. The inclusion of non-academic sources, while appropriate for a scoping review of an emerging topic, means the evidence quality is highly variable.

How to read the evidence

This is a scoping review, which maps the state of knowledge rather than testing a specific hypothesis. The review is thorough in documenting what's known, but what's known is very little — especially regarding human safety and health effects.

When this study was published

Published in 2023. The delta-8 regulatory landscape continues to shift rapidly. Some findings about legal status may already be outdated.

The bigger picture

Delta-8 highlights a recurring theme in the cannabis research database: the gap between consumer access and scientific understanding. The potency market analysis in RTHC-00086 (THC:CBD ratios in dispensaries) showed how the regulated cannabis market overshoots therapeutic targets. Delta-8 takes this a step further — an entire product category exists outside regulated markets entirely, with no quality standards, no potency verification, and no safety testing.

Replication

Not stated in abstract.

Funding

Not reported in abstract.

Conflicts of interest

Not reported in abstract.

Questions still open

What are the actual pharmacological differences between delta-8 and delta-9 THC in humans? Are the byproducts of chemical conversion from CBD to delta-8 harmful? Should delta-8 be regulated like delta-9 cannabis, or banned entirely until safety data exists? How many adolescents are using delta-8 products, and what are the health consequences?

Read the original research

Delta-8 tetrahydrocannabinol: a scoping review and commentary

Addiction, 118(6), 1011-1028

Addiction is a well-respected journal focusing on substance use and addiction research.

View on PubMed ↗Publisher’s paper ↗

Citation

LoParco, Cassidy R.; Rossheim, Matthew E.; Walters, Scott T.; Zhou, Zhengyang; Olsson, Sofia; Sussman, Steve Y.. (2023). Delta-8 tetrahydrocannabinol: a scoping review and commentary. Addiction, 118(6), 1011-1028. https://doi.org/10.1111/add.16142